N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: A case-control study

Arthritis Research and Therapy

Volumn 14, Issue 3, 2012, Pages

  Thakkar, Vivek ^a   Stevens, Wendy M ^a   Prior, David ^a   Moore, Owen A ^a   Byron, Jillian ^a   Liew, Danny ^b   Patterson, Karen ^c   Hissaria, Pravin ^c,d   Roddy, Janet ^e   Zochling, Jane ^f   Sahhar, Joanne ^g   Nash, Peter ^h   Tymms, Kathleen ⁱ   Celermajer, David ^j   Gabbay, Eli ^e   Youssef, Peter ^j   Proudman, Susanna M ^d   Nikpour, Mandana ^a,k  

^a ST VINCENT S HOSPITAL   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^d ROYAL ADELAIDE HOSPITAL   (Australia)

^e ROYAL PERTH HOSPITAL   (Australia)

^f The Menzies Institute   (Australia)

^g MONASH MEDICAL CENTRE   (Australia)

^h Sunshine Coast Rheumatology   (Australia)

ⁱ Canberra Rheumatology   (Australia)

^j ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^k UNIVERSITY OF MELBOURNE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; DIAGNOSTIC AGENT; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; ALGORITHM; ANALYSIS OF VARIANCE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HEART CATHETER; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; PREDICTION; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; RECEIVER OPERATING CHARACTERISTIC; SCREENING; SENSITIVITY AND SPECIFICITY; SYSTEMIC SCLEROSIS; SYSTOLIC BLOOD PRESSURE; TRANSTHORACIC ECHOCARDIOGRAPHY; AGED; AREA UNDER THE CURVE; BLOOD; CASE CONTROL STUDY; EARLY DIAGNOSIS; MIDDLE AGED; ONSET AGE;

ADULT; AGE OF ONSET; AGED; ALGORITHMS; AREA UNDER CURVE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; EARLY DIAGNOSIS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; ROC CURVE; SCLERODERMA, SYSTEMIC; SENSITIVITY AND SPECIFICITY;

EID: 84861987344     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3876     Document Type: Article

References (30)

1. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007, 66:940-944. 10.1136/ard.2006.066068, 1955114, 17329309.
2. Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, Bancel DF, Allanore Y, Muller-Ladner U, Distler O, Iannone F, Pellerito R, Pileckyte M, Miniati I, Ananieva L, Gurman AB, Damjanov N, Mueller A, Valentini G, Riemekasten G, Tikly M, Hummers L, Henriques MJ, Caramaschi P, Scheja A, Rozman B, Ton E, Kumanovics G, Coleiro B, Feierl E, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010, 69:1809-1815. 10.1136/ard.2009.114264, 20551155.
3. Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JSR, Vrapi F, Das C, Elliot CA, Johnson M, DeSoyza J, Torpy C, Goldsmith K, Hodgkins D, Hughes RJ, Pepke-Zaba J, Coghlan JG. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Critical Care Med 2008, 179:151-157.
4. Launay D, Sitbon O, Le Pavec J, Savale L, Tcherakian C, Yaici A, Achouh L, Parent F, Jais X, Simonneau G, Humbert M. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology 2009, 49:490-500.
5. Hachulla E, Launay D, Yaici A, Berezne A, de Groote P, Sitbon O, Mouthon L, Guillevin L, Hatron PY, Simonneau G, Clerson P, Humbert M. Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome. Rheumatology 2010, 49:940-944. 10.1093/rheumatology/kep449, 20144930.
6. Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB, Miller DP, Nicolls MR, Zamanian RT. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010, 138:1383-1394. 10.1378/chest.10-0260, 20507945.
7. Phung S, Strange G, Chung LP, Leong J, Dalton B, Roddy J, Deague J, Playford D, Musk M, Gabbay E. Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis. Intern Med J 2009, 39:682-691. 10.1111/j.1445-5994.2008.01823.x, 19220532.
8. Galiè N, Rubin LJ, Hoeper MM, Jansa P, Al-Hiti H, Meyer GMB, Chiossi E, Kusic-Pajic A, Simonneau G. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008, 371:2093-2100. 10.1016/S0140-6736(08)60919-8, 18572079.
9. Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006, 65:1336-1340. 10.1136/ard.2005.048967, 1798307, 16793845.
10. Humbert M, Yaici A, de Groote P, Montani D, Sitbon O, Launay D, Gressin V, Guillevin L, Clerson P, Simonneau G, Hachulla E. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 2011, 63:3522-3530. 10.1002/art.30541, 21769843.
11. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association, developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009, 53:1573-1619. 10.1016/j.jacc.2009.01.004, 19389575.
12. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G, Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T, McGregor K, Popescu BA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009, 30:2493-2537.
13. National Pulmonary Hypertension Centres of the UK Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland. Heart 2008, 94:i1-i41. National Pulmonary Hypertension Centres of the UK.
14. Kowal-Bielecka O, Avouac J, Pittrow D, Huscher D, Behrens F, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Strand V, Furst DE, Distler O, . Group E Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group. J Rheumatol 2010, 37:105-115. 10.3899/jrheum.090661, 19955042, Group E.
15. Denton CP, Cailes JB, Phillips GD, Wells AU, Black CM, Bois RM. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 1997, 36:239-243. 10.1093/rheumatology/36.2.239, 9133938.
16. Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, Kahan A, Cabane J, Francès C, Launay D, Mouthon L, Allanore Y, Tiev KP, Clerson P, Groote P, Humbert M. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005, 52:3792-3800. 10.1002/art.21433, 16320330.
17. Hsu VM, Moreyra AE, Wilson AC, Shinnar M, Shindler DM, Wilson JE, Desai A, Seibold JR. Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. J Rheumatol 2008, 35:458-465.
18. Dimitroulas T, Giannakoulas G, Karvounis H, Gatzoulis MA, Settas L. Natriuretic peptides in systemic sclerosis-related pulmonary arterial hypertension. Semin Arthritis Rheum 2010, 39:278-284. 10.1016/j.semarthrit.2009.03.005, 19539354.
19. Allanore Y, Borderie D, Meune C, Cabanes L, Weber S, Ekindjian OG, Kahan A. N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. Arthritis Rheum 2003, 48:3503-3508. 10.1002/art.11345, 14674001.
20. Mukerjee D, Yap LB, Holmes AM, Nair D, Ayrton P, Black CM, Coglan JG. Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. Respir Med 2003, 97:1230-1236. 10.1016/S0954-6111(03)00254-3, 14635979.
21. Allanore Y, Borderie D, Avouac J, Zerkak D, Meune C, Hachulla E, Mouthon L, Guillevin L, Meyer O, Ekindjian OG, Weber S, Kahan A. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 2008, 58:284-291. 10.1002/art.23187, 18163505.
22. Masi AT, . The Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980, 23:581. 10.1002/art.1780230510, 7378088, The Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.
23. LeRoy EC, Medsger TA. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001, 28:1573-1576.
24. Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, Gustafsson P, Hankinson J, Jensen R, McKay R, Miller MR, Navajas D, Pedersen OF, Pellegrino R, Wanger J. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005, 26:720-735. 10.1183/09031936.05.00034905, 16204605.
25. Williams MH, Handler C, Akram R, Smith CJ, Das C, Smee J, Nair D, Denton CP, Black CM, Coghlan J. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 2005, 27:1485-1494.
26. Nishikimi T, Ikeda M, Takeda Y, Ishimitsu T, Shibasaki I, Fukuda H, Kinoshita H, Nakagawa Y, Kuwahara K, Nakao K. The effect of glycosylation on plasma N-terminal proBNP-76 levels in patients with heart or renal failure. Heart 2012, 98:152-161. 10.1136/heartjnl-2011-300102, 21719557.
27. Le Pavec J, Girgis RE, Lechtzin N, Mathai SC, Launay D, Hummers LK, Zaiman A, Sitbon O, Simonneau G, Humbert M, Hassoun PM. Systemic sclerosis related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. Arthritis Rheum 2011, 63:2456-2464. 10.1002/art.30423, 21538327.
28. Corte TJ, Wort SJ, Gatzoulis MA, Engel R, Giannakoulas G, Macdonald PM, Wells AU. Elevated brain natriuretic peptide predicts mortality in interstitial lung disease. Eur Respir J 2010, 36:819-825. 10.1183/09031936.00173509, 20223915.
29. Leuchte HH, Baumgartner RA, Nounou ME, Vogeser M, Neurohr C, Trautnitz M, Behr J. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med 2006, 173:744-750. 10.1164/rccm.200510-1545OC, 16415273.
30. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009, 34:888-894. 10.1183/09031936.00145608, 19324955.